**A retrospective study comparing the outcomes and toxicities of intensity-modulated radiotherapy versus two-dimensional conventional radiotherapy for the treatment of children and adolescent nasopharyngeal carcinoma**

Wen-Ze Qiu$^{1,2}$ · Xing-Si Peng$^{1,2}$ · Hai-Qun Xia$^{1,2}$ · Pei-Yu Huang$^{1,2}$ · Xiang Guo$^{1,2}$ · Ka-Jia Cao$^{1,2}$

Received: 21 January 2017 / Accepted: 17 March 2017 / Published online: 25 March 2017 © The Author(s) 2017. This article is an open access publication

**Abstract**

**Purpose** To compare the clinical outcomes and toxicities of two-dimensional conventional radiotherapy (2D-CRT) and intensity-modulated radiotherapy (IMRT) for the treatment of children and adolescent nasopharyngeal carcinoma (NPC).

**Methods** A total of 176 children with non-metastatic NPC treated at Sun Yat-sen University Cancer Center between October 2003 and September 2013 were included in this study. Of the 176 patients, 74 received 2D-CRT and 102 were treated with IMRT. The clinical outcomes and acute and late toxicities were determined and compared.

**Results** The IMRT group achieved significantly higher overall survival (OS) (90.4% vs. 76.1% at 5 year, $P=0.007$) and disease-free survival (DFS) (85.7% vs. 71.2%, $P=0.029$) mainly due to an improvement in locoregional relapse-free survival (LRRFS) (97.9 vs. 88.3%, $P=0.049$). After stratification by disease stage, IMRT provided significant benefits for patients with stage III–IV disease in terms of OS, LRRFS and DFS. Multivariate analyses indicated that the treatment group (2D-CRT vs. IMRT) was a prognostic factor for OS, LRRFS and DFS. A significant reduction in Grade 2–4 xerostomia (52.7 vs. 34.3%, $P=0.015$) and hearing loss (40.5 vs. 22.5%, $P=0.010$) was observed in patients treated by IMRT.

**Conclusion** IMRT provides better locoregional relapse-free survival and overall survival, especially in late-stage children and adolescent NPC patients, and is associated with a lower incidence of Grade 2–4 xerostomia as well as hearing loss compared with 2D-CRT. Distant metastasis remains a challenge in the treatment of children and adolescent NPC.

**Keywords** Nasopharyngeal carcinoma · Children and adolescents · Two-dimensional conventional radiotherapy · Intensity-modulated radiotherapy · Treatment result

**Abbreviations**

2D-CRT Two-dimensional conventional radiotherapy
IMRT Intensity-modulated radiotherapy
SIB-IMRT Simultaneous integrated boost intensity-modulated radiotherapy
NPC Nasopharyngeal carcinoma
OS Overall survival
DFS Disease-free survival
LRRFS Locoregional relapse-free survival
DMFS Distant metastasis-free survival
LRC Locoregional control
EBV Epstein–Barr virus
CT Computed tomography
MRI Magnetic resonance imaging
GTV Gross tumour volume
CTV Clinical tumour volume
PTV Planning target volume
CTC Common Toxicity Criteria
TLI Temporal lobe injury
TLN Temporal lobe necrosis
NAC Neoadjuvant chemotherapy
Background

Nasopharyngeal carcinoma (NPC) is endemic in Southeast Asian countries, where the incidence rates range from 30 to 50 in 100,000 people. NPC is strongly associated with Chinese ethnic origin (Wei and Sham 2005; Wei et al. 2014). In most other populations, the disease is rare, with an intermediate incidence in Mediterranean basin countries and Greenland (Wei and Sham 2005). One remarkable difference between Mediterranean and Asian NPCs is the age distribution. Although a unimodal peak at 50–60 years exists among endemic countries, an additional minor early peak appears at 10–20 years of age among Mediterranean countries (Ayan et al. 2003). NPC in children differs from that of their adult counterparts in its close association with Epstein–Barr virus (EBV) infection, its undifferentiated histology, and the high incidence of locoregionally advanced disease (Ayan et al. 2003; Young and Dawson 2014).

The optimal treatment modality in children has not been established to date. The treatment recommendations for childhood NPC typically follow guidelines established for adults. Previous studies have reported that in paediatric and adolescent NPC patients treated with two-dimensional conventional radiotherapy (2D-CRT), the 5-year overall survival rate varied from 55 to 80%, with an incidence of late sequelae of 65–85% (Wolden et al. 2000; Hu et al. 2013).

Intensity-modulated radiotherapy (IMRT) is an innovative modality with the overall goal of providing a high dose of radiation to the tumour bed to achieve local control while attempting to spare the critical surrounding structures from high-dose radiation damage (Kwong et al. 2004). According to experiences with the use of IMRT for adults with NPC (Peng et al. 2012; Mao et al. 2015), it is expected that implementation of IMRT for children and adolescent NPC would also translate into an improved outcome with reduced treatment-related toxicities. However, studies that examine the application of IMRT in children and adolescent NPC are rare (Laskar et al. 2008; Guo et al. 2015), and no evidence has demonstrated significant advantages of IMRT compared with 2D-CRT regarding the survival rate and late treatment-related toxicities. The purpose of this retrospective study is to assess whether the use of IMRT is associated with improved clinical outcomes and reduced treatment-related toxicities compared with 2D-CRT in children and adolescent NPC.

Methods

Patient population

A total of 176 children with NPC were treated at the Sun Yat-sen University Cancer Center from October 2003 to September 2013. Patients were 7–20 years of age and histologically diagnosed with untreated non-metastatic NPC. Of the 176 patients, 129 were boys and 47 were girls (male/female ratio, 2.74:1). Most patients (69, 39.2%) presented with cervical lymphadenopathy. Other common presenting symptoms included epistaxis (35, 19.9%), tinnitus (28, 15.9%), headache (21, 11.9%), nasal obstruction or discharge (20, 11.4%), trismus (2, 1.1%) and facial numbness (1, 0.6%). Pretreatment evaluations included a complete history and physical examination, endoscopy and biopsy, complete blood count determination, liver and renal function tests, chest X-ray, and computed tomography (CT) or magnetic resonance imaging (MRI) of the head-and-neck region. CT scans of the abdominopelvis or chest, bone scans, and positron emission tomography scans were performed when clinically indicated. Patients underwent clinical staging according to the American Joint Committee on Cancer staging system (seventh edition). The medical ethics committee of Sun Yat-Sen University Cancer Center approved the study. All patients were treated under the principles of the Helsinki declaration.

Treatment methods

2D-CRT

The details of the 2D-CRT techniques utilized in our cancer centre were previously reported (Lai et al. 2011). Patients were immobilized in the supine position with a thermoplastic mask and treated with two lateral opposing faciocervical portals to irradiate the nasopharynx and upper neck in one volume followed by application of the shrinking-field technique to limit irradiation of the spinal cord. An anterior cervical field was used to treat the neck with a laryngeal block. The accumulated radiation doses were 66–80 GY (median, 70 GY), with 2 GY per fraction applied to the primary tumour, 60–64 GY applied to the involved areas of the neck, and 50 GY applied to the uninvolved areas. All patients were treated with one fraction daily for 5 days per week.

A boost portal was performed if necessary. Different radiation energies, including megavoltage photons (6 or 8 MV) and electrons, were used. A boost dose (8 to 12 GY per 4–6 fractions) was delivered to the skull base in patients with NPC involving the skull base and intracranial extension.
IMRT

The IMRT technique has also been described previously (Zhang et al. 2015). All patients were immobilized in the supine position with a head, neck, and shoulder thermoplastic mask. Two sets of images with and without contrast were obtained from the computed tomography (CT) simulator for treatment planning. All patients were scanned with serial 3-mm slices from the vertex through the clavicles. The gross tumour volumes of the nasopharynx (GTVnx) and positive neck lymph nodes (GTVnd) were delineated according to our previously described institutional treatment protocol (Zhao et al. 2004), which is in agreement with the International Commission on Radiation Units and Measurements Reports 50 and 62. The first clinical tumour volume (CTV1) was defined as the GTVnx plus a margin of 5–10 mm for potential microscopic spread, including the entire nasopharyngeal mucosa plus a 5-mm submucosal volume. The second CTV (CTV2) was defined by adding a margin of 5–10 mm to CTV1 and included the following regions, which required prophylactic irradiation: the retropharyngeal lymphnode regions, clivus, skull base, pterygoid fossae, parapharyngeal space, inferior sphenoid sinus, posterior edge of the nasal cavity, maxillary sinuses, and lymphatic drainage area. The planning target volume (PTV) for GTVs and CTVs were generated automatically by adding a 5-mm margin after delineation of tumour targets according to the immobilization and localization uncertainties. The prescribed dose was 62–70 Gy (median, 68 Gy) to the PTV of the GTVnx (PTVnx), 58–66 Gy to the PTV of the GTVnd (PTVnd), 56–64 Gy to the PTV of the CTV1 (PTV1), and 50–58 Gy to the PTV of the CTV2 (PTV2) in 28–33 fractions. All patients were treated with one fraction daily over 5 days per week. The doses limited to the major organs at risk were as follows: the brain stem, with a 3-mm margin, $D_{\text{max}} < 54$ Gy; spinal cord, with a 5-mm margin, $D_{\text{max}} < 40$ Gy; the optic nerve, chiasm and temporal lobe, $D_{\text{max}} < 54$ Gy; the parotid gland, V30–35 < 50%.

Follow-up

Patients received follow-up every 3 months for the first 3 years after RT, every 6 months for years 3–5 and annually thereafter. Follow-up included physical examinations, chest X-ray, abdominal ultrasonography, MRI of the head and neck and/or bone scan. Late therapy-related complications were scored according to the Common Toxicity Criteria (CTC) version 3.0 of the U.S. National Institutes of Health. The last follow-up date was December 31, 2015.

Statistical analysis

The following endpoints were assessed: overall survival (OS), locoregional relapse-free survival (LRRFS), distant metastasis-free survival (DMFS), and disease-free survival (DFS). OS was defined as the time from the start of RT to death by any cause. LRRFS was defined as the time from the start of RT to the first occurrence of local or regional recurrence. DMFS was defined as the time from the start of RT to the first occurrence of distant metastasis. DFS was defined as the time from the start of RT to the first occurrence of local or regional recurrence or distant metastasis. Pearson’s $\chi^2$ tests were used to explore the differences between categorical variables. The actuarial rates were generated according to the methods of Kaplan and Meier. Differences between survival curves were compared using the log-rank test. Multivariate analysis was conducted by the Cox proportional hazard regression model. A $p$ value of less than 0.05 was considered significant. Statistical analysis was performed using SPSS software, version 20.0 (SPSS, Chicago, IL).

Results

Patients’ clinicopathological characteristics

The characteristics of patients in the IMRT group and 2D-CRT group are presented in Table 1. A total of 102 patients received IMRT, and 74 received 2D-CRT. The groups were comparable with respect to the host factors, pathologic type, disease stage, and the use of chemotherapy (all, $p > 0.05$). The median follow-up time was 52 months (range 3–136 months).

Patterns of treatment failure

Thirty-four patients (19.3%) failed during follow-up, including nine in locoregional relapse, 23 in distant metastasis and two in both (Table 2). The median failure times were 13 months (3–86 months) and 14 months (3–77 months) for locoregional relapse and distant metastasis,
respectively. At the latest follow-up, 18 patients in the 2D-CRT group and 6 in the IMRT group died. The cause of death was related to recurrent cancer in 17 patients (94.4%) in the 2D-CRT group and 6 patients (100%) in the IMRT group.

### Survival analysis

**OS**

Figure 1a shows OS curves for patients in both study groups. At 5 years, the OS rates were 76.1% for the 2D-CRT group and 90.4% for the IMRT group. The difference was statistically significant (Hazard Ratio (HR): 0.30; 95% confidence interval (CI): 0.12–0.78; \(P = 0.007\)). After stratification for the overall stage, the 5-year OS for stage III–IV disease for the IMRT group was increased compared to that of the 2D-CRT group (\(P = 0.011\)). After stratification for the T stage and N stage, the OS at 5 years was significantly greater for the IMRT group for patients with T3–4 or N2–3 disease (\(P = 0.021\), \(P = 0.025\), respectively).

**LRRFS**

Figure 1b presents the LRRFS curves for the patients in both study groups. A significant difference in LRRFS was observed between the groups (HR: 0.28; 95% CI: 0.07–0.98; \(P = 0.049\)). The LRRFS rates at 5 years were 88.3% in the 2D-CRT group and 97.9% in the IMRT group. The results of stratification for the overall stage revealed a borderline significant difference in LRRFS, favouring treatment with IMRT in patients with stage III–IV disease (HR: 0.29; 95% CI: 0.08–1.10; \(P = 0.052\)). After stratification for the T stage and N stage, no significant difference in LRRFS was observed between the groups.

**DMFS**

Figure 1c shows the DMFS curves for the study groups. There was no significant difference between the groups (HR: 0.61; 95% CI: 0.27–1.34; \(P = 0.211\)). The 5-year DMFS rates were 80.1% in the 2D-CRT group and 86.6% in the IMRT group. After stratification for the overall stage, T stage and N stage, no significant difference in DMFS was observed between the groups.

**DFS**

Figure 1d shows DFS curves for patients in both study groups. At 5 years, the DFS rates were 71.2% for the 2D-CRT group and 85.7% for the IMRT group. This difference was statistically significant (HR: 0.47; 95% CI: 0.23–0.94; \(P = 0.029\)). After stratification for the overall stage, T stage and N stage, no significant difference in DFS was observed between the groups.

### Table 1 Characteristics of the 176 patients with paediatric and adolescent nasopharyngeal carcinoma

| Characteristics | 2D-CRT (\%, \(n=74\)) | IMRT (\%, \(n=102\)) | \(P\) |
|-----------------|-------------------------|------------------------|------|
| Gender          |                         |                        | 0.793|
| Male            | 55 (74.3)               | 74 (72.5)              |      |
| Female          | 19 (25.7)               | 28 (27.5)              |      |
| Age (years)     |                         |                        | 0.190|
| \(\leq 14\)     | 14 (18.9)               | 28 (27.5)              |      |
| \(> 14\)        | 60 (81.1)               | 74 (72.5)              |      |
| Pathologic type |                         |                        | 0.369|
| WHO II          | 0 (0)                   | 3 (2.9)                |      |
| WHO III         | 74 (100.0)              | 99 (97.1)              |      |
| T stage         |                         |                        | 0.989|
| T1              | 2 (2.7)                 | 3 (2.9)                |      |
| T2              | 2 (2.7)                 | 7 (6.9)                |      |
| T3              | 37 (50.0)               | 44 (43.1)              |      |
| T4              | 33 (44.6)               | 48 (47.1)              |      |
| N stage         |                         |                        | 0.861|
| N0              | 5 (6.8)                 | 6 (5.9)                |      |
| N1              | 21 (28.4)               | 29 (28.4)              |      |
| N2              | 31 (41.9)               | 48 (47.1)              |      |
| N3              | 17 (23.0)               | 19 (18.6)              |      |
| Overall stage   |                         |                        | 0.823|
| I               | 1 (1.4)                 | 1 (1.0)                |      |
| II              | 1 (1.4)                 | 4 (3.9)                |      |
| III             | 32 (43.2)               | 39 (38.2)              |      |
| IV              | 40 (54.1)               | 58 (56.9)              |      |
| Combination with chemotherapy | | | 0.130|
| No              | 7 (9.5)                 | 3 (2.9)                |      |
| NAC             | 33 (44.6)               | 16 (15.7)              |      |
| CCT             | 15 (20.3)               | 25 (24.5)              |      |
| NAC + CCT       | 19 (25.7)               | 58 (56.9)              |      |

2D-CRT two-dimensional conventional radiotherapy, IMRT intensity-modulated radiotherapy, NAC neoadjuvant chemotherapy, CCT concurrent chemotherapy

### Table 2 Patterns of disease failure in patients treated with 2D-CRT vs. IMRT

| Failure pattern                          | 2D-CRT [cases (%)] | IMRT [cases (%)] | \(P\) |
|------------------------------------------|--------------------|------------------|------|
| Locoregional only                        | 7 (9.5)            | 2 (2.0)          | 0.060|
| Distant metastasis only                  | 13 (17.6)          | 10 (9.8)         | 0.131|
| Both locoregional relapse and distant metastasis | 1 (1.4)            | 1 (1.0)          | 1.000|

2D-CRT two-dimensional conventional radiotherapy, IMRT intensity-modulated radiotherapy
stage and N stage, the DFS at 5 years was significantly greater for the IMRT group for patients with stage III–IV or N2–3 disease ($P = 0.037$, $P = 0.034$, respectively). After stratification for the T stage, no significant difference in DFS was observed between the groups.

Prognostic factors

The value of various potential prognostic factors on predicting OS, LRRFS, DMFS, and DFS was evaluated. Univariate analysis by log-rank test showed that the N stage and treatment group were significantly associated with OS. The treatment group was significantly associated with LRRFS. Age, T stage, N stage, and overall stage were significantly related to DMFS. The T stage, N stage, overall stage and treatment group were significantly related to DFS (Table 3).

Multivariate analysis by Cox proportional-hazards model revealed that the T stage, N stage, overall stage and treatment group were independent prognostic predictors of OS ($P = 0.017$, $P < 0.001$, $P = 0.031$, $P = 0.007$, respectively). The treatment group was the only independent prognostic predictor of LRRFS ($P = 0.041$). The T stage and N stage were independent prognostic predictors of DMFS ($P = 0.012$, $P < 0.001$, respectively). The T stage, N stage and treatment group were independent prognostic predictors of DFS ($P = 0.005$, $P < 0.001$, $P = 0.031$, respectively) (Table 4).

Acute and late toxicities

No significant differences in acute Grade 3–4 toxicities were observed between the two groups (Table 5). With respect to late complications, the rates of Grade 2–4 xerostomia and hearing loss were significantly greater in the 2D-CRT group compared with the IMRT group (Table 6). Of note, one patient in the 2D-CRT group died of severe radiation encephalopathy after 88 months.

Discussion

IMRT is an ideal radiation modality for NPC given its potential for excellent target coverage and normal tissue sparing. Several published meta-analyses are encouraging, demonstrating that IMRT not only improves locoregional control and survival but also reduces acute and late toxicities (Penagaricano and Papanikolaou 2003, 2012).
### Table 3  Univariate analysis of prognostic factors for paediatric and adolescent nasopharyngeal carcinoma

| Variate                     | OS       | P       | LRRFS    | P       | DMFS    | P       | DFS     | P       |
|-----------------------------|----------|---------|----------|---------|---------|---------|---------|---------|
| Gender                      | 0.535    | 0.533   | 0.436    | 0.403   |         |         |         |         |
| Male                        | 81.5     | 93.2    | 82.2     | 77.7    |         |         |         |         |
| Female                      | 89.9     | 95.3    | 87.5     | 83.2    |         |         |         |         |
| Age                         | 0.886    | 0.292   | 0.023    | 0.243   |         |         |         |         |
| ≤14                         | 88.0     | 89.1    | 97.6     | 86.7    |         |         |         |         |
| >14                         | 82.7     | 95.2    | 79.9     | 77.2    |         |         |         |         |
| T stage                     | 0.166    | 0.192   | 0.004    | 0.004   |         |         |         |         |
| T1–3                        | 88.5     | 95.6    | 90.8     | 86.7    |         |         |         |         |
| T4                          | 78.1     | 91.6    | 75.4     | 70.6    |         |         |         |         |
| N stage                     | <0.001   | 0.079   | <0.001   | <0.001  |         |         |         |         |
| N0–2                        | 88.8     | 95.2    | 88.8     | 84.4    |         |         |         |         |
| N3                          | 62.3     | 87.6    | 61.8     | 57.8    |         |         |         |         |
| Overall stage               | 0.212    | 0.197   | 0.022    | 0.015   |         |         |         |         |
| Stage I–III                 | 85.4     | 96.0    | 90.2     | 86.4    |         |         |         |         |
| Stage IV                    | 79.7     | 92.0    | 78.4     | 73.5    |         |         |         |         |
| Treatment group             | 0.007    | 0.049   | 0.211    | 0.029   |         |         |         |         |
| 2D-CRT                      | 76.1     | 88.3    | 80.1     | 71.2    |         |         |         |         |
| IMRT                        | 90.4     | 97.9    | 86.6     | 85.7    |         |         |         |         |
| Chemotherapy                | 0.492    | 0.356   | 0.167    | 0.102   |         |         |         |         |
| No                          | 100      | 100     | 100      | 100     |         |         |         |         |
| Yes                         | 82.5     | 93.4    | 82.5     | 77.9    |         |         |         |         |
| Neoadjuvant chemotherapy    | 0.686    | 0.532   | 0.955    | 0.590   |         |         |         |         |
| No                          | 83.1     | 95.0    | 83.2     | 80.2    |         |         |         |         |
| Yes                         | 84.2     | 90.9    | 85.3     | 77.1    |         |         |         |         |
| Concurrent chemotherapy      | 0.472    | 0.748   | 0.507    | 0.338   |         |         |         |         |
| No                          | 85.3     | 94.6    | 84.4     | 80.1    |         |         |         |         |
| Yes                         | 78.4     | 94.8    | 81.1     | 76.4    |         |         |         |         |

2D-CRT two-dimensional conventional radiotherapy, IMRT intensity-modulated radiotherapy, OS overall survival, LRRFS locoregional relapse-free survival, DMFS distant metastasis-free survival, DFS disease-free survival

### Table 4  Multivariate analysis of prognostic factors for paediatric and adolescent nasopharyngeal carcinoma

| Variate                     | OS       |         | LRRFS    |         | DMFS    |         | DFS     |         |
|-----------------------------|----------|---------|----------|---------|---------|---------|---------|---------|
| Gender                      |          |         |          |         |         |         |         |         |
| Male vs. female             | 1.12     | 0.834   | 0.88     | 0.38    | 0.135   | 0.968   | 0.901   | 0.97    |
| Age                         | 0.61     | 0.348   | 0.38     | 0.10    | 0.135   | 0.555   | 0.095   | 1.33    |
| ≤14 vs. >14                 | 6.66     | 0.017   | 3.53     | 0.35    | 0.284   | 14.14   | 0.012   | 8.63    |
| T stage                     | 11.94    | <0.001  | 4.37     | 0.89    | 0.069   | 7.84    | <0.001  | 6.41    |
| N stage                     | 0.12     | 0.031   | 0.47     | 0.03    | 0.591   | 0.11    | 0.066   | 0.19    |
| Overall stage               | 0.27     | 0.007   | 0.24     | 0.06    | 0.041   | 0.65    | 0.299   | 0.46    |
| Treatment group             |          |         |          |         |         |         |         |         |

2D-CRT two-dimensional conventional radiotherapy, IMRT intensity-modulated radiotherapy, OS overall survival, LRRFS locoregional relapse-free survival, DMFS distant metastasis-free survival, DFS disease-free survival

 Springer
However, because children and adolescents with NPC who meet the strict selection criteria accounted for only a small part of these studies, the real role of IMRT in this population remains unclear. Our current study aimed to assess whether the use of IMRT is associated with improved clinical outcomes and reduced treatment-related toxicities compared with 2D-CRT in children and adolescent NPC.

The results of this retrospective study comparing 2D-CRT with IMRT for the treatment of children and adolescent NPC showed that IMRT was associated with improved locoregional control and overall survival, especially for late-stage, non-metastatic disease, and a lower incidence of late toxicities.

In our study, improvement of locoregional control in the IMRT group for stage I/II patients was not remarkable. We hypothesize that the reason for this may be that 2D-CRT provides excellent locoregional control in early-stage NPC patients. However, the sample size of stage I/II (2 patients for 2D-CRT group and 5 for IMRT group) is insufficient to be statistically representative. Our results showed that the locoregional control rate was marginally significantly greater for non-metastatic stage III, and stage IVa and IVb patients in the IMRT group compared with the 2D-CRT group ($P = 0.052$). The tumour may extend close to the adjacent critical structures in patients with locoregionally advanced NPC, and the 2D-CRT dose and coverage often have to be compromised to avoid unacceptable complications, resulting in poor disease control. The aim of treatment for locoregionally advanced disease is to improve locoregional control by escalating the radiation dose in the tumour without exceeding the tolerance of the adjacent critical structures. IMRT can deliver a higher total dose and dose per fraction to the target volume and maintain low doses to the adjacent critical structures (Laskar et al. 2008).

A prospective, randomized study by Peng et al. compared the outcomes and toxicities of IMRT vs. 2D-CRT for the treatment of NPC, and the result showed that better local recurrence-free survival and a lower incidence of toxicities can be achieved in the IMRT group for late-stage NPC patients (Peng et al. 2012). In the current study, the NPC failure pattern was not altered by IMRT, and distant metastasis remained the major pattern of failure in paediatric and adolescent NPC, a result similar to the findings of other reports (Tao et al. 2013; Guo et al. 2015). The relatively short time to systemic failure in the absence of locoregional failure might suggest that subclinical metastasis

### Table 5  Acute Grade 3–4 toxicities in patients treated with 2D-CRT versus IMRT

| Acute toxicity | 2D-CRT ($n = 74, \%$) | IMRT ($n = 102, \%$) | $P$ |
|---------------|----------------------|----------------------|-----|
|               | Grade 3 | Grade 4 | All | Grade 3 | Grade 4 | All |
| Leucopenia    | 4 (5.4) | 1 (1.4) | 5 (6.8) | 13 (12.7) | 0 | 13 (12.7) | 0.196 |
| Neutropenia   | 5 (6.8) | 1 (1.4) | 6 (8.2) | 11 (10.8) | 5 (4.9) | 16 (15.8) | 0.133 |
| Anaemia       | 2 (2.7) | 0 | 2 (2.7) | 2 (2.0) | 0 | 2 (2.0) | 1.000 |
| Thrombocytopenia | 0 | 1 (1.4) | 1 (1.4) | 3 (2.9) | 0 | 3 (2.9) | 0.640 |
| Hepatotoxicity | 1 (1.4) | 0 | 1 (1.4) | 0 | 0 | 0 | 0.420 |
| Nephrotoxicity | 1 (1.4) | 0 | 1 (1.4) | 1 (1.0) | 1 (1.0) | 2 (2.0) | 1.000 |
| Dermatitis    | 6 (8.1) | 0 | 6 (8.1) | 3 (2.9) | 0 | 3 (2.9) | 0.234 |
| Stomatitis    | 16 (21.6) | 0 | 16 (21.6) | 18 (17.6) | 0 | 18 (17.6) | 0.510 |
| Hearing loss  | 1 (1.4) | 0 | 1 (1.4) | 0 | 0 | 0 | 0.420 |
| Total any     | 28 (37.8) | 1 (1.4) | 29 (39.2) | 40 (39.2) | 6 (5.9) | 46 (45.1) | 0.434 |

### Table 6  Late toxicities in patients treated with 2D-CRT versus IMRT

| Late toxicity | 2D-CRT ($n = 74, \%$) | IMRT ($n = 102, \%$) | $P$ |
|---------------|----------------------|----------------------|-----|
| Xerostomia*   | 39 (52.7) | 35 (34.3) | 0.015 |
| Hearing loss* | 30 (40.5) | 23 (22.5) | 0.010 |
| Skin dystrophy | 29 (39.2) | 30 (29.4) | 0.175 |
| Neck fibrosis | 25 (33.8) | 22 (21.6) | 0.071 |
| Trismus       | 11 (14.9) | 8 (7.8) | 0.138 |
| Radiation encephalopathy | 6 (8.1) | 4 (3.9) | 0.236 |
| Cranial nerve palsy | 7 (9.5) | 4 (3.9) | 0.134 |
| Growth retardation | 3 (4.1) | 2 (2.0) | 0.409 |

2D-CRT two-dimensional conventional radiotherapy, IMRT intensity-modulated radiotherapy

*Grade 2–4 toxicities
that likely existed at first treatment required early systemic treatment. Two prospective multicentre studies, NPC-91-GPOH (Mertens et al. 2005) and NPC-2003-GPOH/DCOG (Buehrlen et al. 2012), demonstrated favourable results for multimodal treatment (neoadjuvant chemotherapy, and radiotherapy followed by interferon-β) in patients with paediatric and adolescent NPC. After a median follow-up time of 30 months and 48 months, the overall survival and event-free survival rates were 95–97% and 91–92.4%, respectively. These promising outcomes indicate that interferon-β may provide a survival benefit in patients with paediatric NPC. However, further studies are needed to investigate the most effective chemotherapy regimens and their optimal timing with IMRT.

With better outcomes and longer survival, the prevention of radiation-induced complications becomes more important, and several studies have demonstrated quality of life advantages with IMRT in children with NPC (Tao et al. 2013; Guo et al. 2015). Laskar et al. (2008) compared 2D-CRT with IMRT in 36 cases of paediatric and adolescent NPC. A significant reduction in acute Grade 3 toxicities of the skin, mucous membrane, and pharynx was noted with the use of IMRT despite similar survival rates between the two groups. Moreover, the median time to the development of Grade 2 toxicities, including skin toxicity and mucositis, was delayed with IMRT. Tao et al. (2013) assigned 34 children with non-disseminated NPC to evaluate the long-term outcome and late toxicities with simultaneous integrated boost-intensity-modulated radiotherapy (SIB-IMRT). Grades 1–2 xerostomia and ototoxicity were the most common late toxicities. Only two patients (8.3%) developed grade 3 xerostomia, and no patients developed grade 4 toxicities. The 5-year LRRFS, DMFS, DFS, and OS were 97.1, 88.2, 85.3, and 88.2%, respectively, which were comparable to the present data, confirming that an improved outcome and reduced toxicity could be achieved by IMRT in young NPC patients. Liu et al. (2014) studied 158 childhood and adolescence NPC patients to compare IMRT with 2D-CRT. The result revealed that IMRT significantly reduces trismus (27.3 vs. 3.6%, \(P = 0.03\)) and Grade 2 xerostomia (37.9 vs. 10.3%, \(P = 0.02\)); however, no survival benefits are achieved with the use of IMRT. Similarly, our study reported a significant reduction of Grade 2–4 xerostomia and hearing loss (\(P = 0.015\), \(P = 0.010\), respectively) using IMRT.

As one of the most feared complications after radical radiotherapy, temporal lobe injury (TLI) can be devastating for patients and accounts for approximately 65% of deaths from radiation-induced toxicities (Lee et al. 1992). The results from our study revealed a trend of higher incidence of radiation encephalopathy in 2D-CRT compared with IMRT (8.1 vs. 3.9%, \(P = 0.236\)), and one patient in the 2D-CRT group died of severe radiation encephalopathy in 88 months. Zhou et al. (2013) reported that IMRT significantly reduced the incidence of radiation-induced TLI compared with the 2D-CRT (7.5 vs. 10.8%, \(P = 0.048\)). Mao et al. (2014) also observed less extensive and milder temporal lobe necrosis (TLN) in the IMRT group. We hypothesize that the improvement observed with IMRT is largely due to the technical advantages of IMRT. Compared with opposed lateral fields in conventional 2D radiation therapy, modern IMRT utilizes multiple small segments of beams (pencil beams), and the intensities of the neighbouring pencil beams vary. Collectively, beams composed of segments with different intensities produce dose distributions that conform to the required shape of the targets. Furthermore, the popular adopted simultaneous integrated boost (SIB) dosing regimen has the advantage of providing a more conformal dose distribution, thereby facilitating enhanced sparing of critical normal structures (Chen et al. 2005).

To the best of our knowledge, the present analysis is the only study reporting significant advantages of IMRT compared with 2D-CRT regarding the survival rate and late treatment-related toxicities in children and adolescent NPC. Our study, however, has several limitations. The main limitation is its retrospective nature and the sample size. The establishment of treatment guidelines for paediatric NPC is needed through multi-centre collaboration on randomized controlled trials. Furthermore, radiation-induced toxicities may develop over time, especially for young patients, and a longer follow-up period is desirable to determine the exact incidences of these complications and the actual superiority of IMRT in reducing late toxicities (e.g. endocrinopathies, cranial nerve palsy, and second neoplasms).

In conclusion, IMRT provides better locoregional relapse-free survival and overall survival, especially in late-stage children and adolescent NPC patients and is associated with a lower incidence of Grade 2–4 xerostomia and hearing loss compared with 2D-CRT. Distant metastasis remains a challenge in the treatment of children and adolescent NPC.

Author contributions Ka-Jia Cao conceived the study. Wen-Ze Qiu and Xing-Si Peng drafted the manuscript. Hai-Qun Xia and Pei-Yu Huang collected the data and generated the clinical database. Xiang Guo performed the analysis. All authors reviewed and approved the manuscript.

Compliance with ethical standards

Conflict of interest No conflicts of interest.

Ethical approval All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
Informed consent  Informed consent was obtained and chart reviews were performed after approval by the ethics committee of Sun Yat-Sen University Cancer Center.

Availability of data and materials  Datasets can be retrieved from authors upon formal request from interested readers. Datasets cannot be directly shared on public repositories due to the national personal data protection act.

Open Access  This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

Ayan L, Kaytan E, Ayan N (2003) Childhood nasopharyngeal carcinoma: from biology to treatment [J]. Lancet Oncol 4(1):13–21

Bhide SA, Nutting CM (2010) Advances in radiotherapy for head and neck cancer [J]. Oral Oncol 46(6):439–441

Buehrle M, Zwaan CM, Granzen B, Lassay L, Deutz P, Vorwerk P et al (2012) Multimodal treatment, including interferon beta, of nasopharyngeal carcinoma in children and young adults: preliminary results from the prospective, multicenter study NPC-2003-GPOH/DCOG[J]. Cancer 118(19):4892–4900

Chen SW, Yang SN, Liao JA, Shiu AC, Lin FJ (2005) Comparative dosimetric study of two strategies of intensity-modulated radiotherapy in nasopharyngeal cancer[J]. Med Dosi 30(4):219–227

Cheuk DK, Billups CA, Martin MG, Roland CR, Ribeiro RC, Krasin MJ et al (2011) Prognostic factors and long-term outcomes of childhood nasopharyngeal carcinoma [J]. Cancer 117(1):197–206

Daoud J, Toumi N, Bouaziz M, Ghorbel A, Jlidi R, Drira MM et al (2003) Nasopharyngeal carcinoma in childhood and adolescence [J]. Eur J Cancer 39(16):2349–2354

Fang FM, Chien CY, Tsai WL, Chen HC, Hsu HC, Lui CC et al (2008) Quality of life and survival outcome for patients with nasopharyngeal carcinoma receiving three-dimensional conformal radiotherapy vs. intensity-modulated radiotherapy—a longitudinal study [J]. Int J Radiat Oncol Biol Phys 72(2):356–364

Guo Q, Cui X, Lin S, Lin J, Pan J (2015) Nasopharyngeal carcinoma in childhood and adolescence with locoregionally advanced stage: analysis of a series of 95 patients treated with combined chemotherapy and intensity modulated radiation therapy [J]. Head Neck 38:E665–E672

Hu S, Xu X, Xu J, Xu Q, Liu S (2013) Prognostic factors and long-term outcomes of nasopharyngeal carcinoma in children and adolescents [J]. Ped Blood Cancer 60(7):1122–1127

Kwong DL, Pow EH, Sham JS, McMillan AS, Leung LH, Leung WK et al (2004) Intensity-modulated radiotherapy for early-stage nasopharyngeal carcinoma: a prospective study on disease control and preservation of salivary function [J]. Cancer 101(7):1584–1593

Lai SZ, Li WF, Chen L, Luo W, Chen YY, Liu LZ et al (2011) How does intensity-modulated radiotherapy versus conventional two-dimensional radiotherapy influence the treatment results in nasopharyngeal carcinoma patients? [J]. Int J Radiat Oncol Biol Phys 80(3):661–668

Laskar S, Bahl G, Muckaden M, Pai SK, Gupta T, Banavali S et al (2008) Nasopharyngeal carcinoma in children: comparison of conventional and intensity-modulated radiotherapy [J]. Int J Radiat Oncol Biol Phys 72(3):728–736

Lee AW, Law SC, Ng SH, Chan DK, Poon YF, Foo W et al (1992) Retrospective analysis of nasopharyngeal carcinoma treated during 1976–1985: late complications following megavoltage irradiation [J]. Br J Radiol 65(778):918–928

Lee N, Puri DR, Blanco AI, Chao KS (2007) Intensity-modulated radiation therapy in head and neck cancers: an update [J]. Head Neck 29(4):387–400

Liu W, Tang Y, Gao L, Huang X, Luo J, Zhang S et al (2014) Nasopharyngeal carcinoma in children and adolescents— a single institution experience of 158 patients [J]. Radiol Oncol 9(1):274

Lu H, Yao M (2008) The current status of intensity-modulated radiation therapy in the treatment of nasopharyngeal carcinoma [J]. Cancer Treat Rev 34(1):27–36

Mao YP, Zhou GQ, Liu LZ, Guo R, Sun Y, Li L et al (2014) Comparison of radiological and clinical features of temporal lobe necrosis in nasopharyngeal carcinoma patients treated with 2D radiotherapy or intensity-modulated radiotherapy [J]. Br J Cancer 110(11):2633–2639

Mao YP, Yin WJ, Guo R, Zhang GS, Fang JL, Chi F et al (2015) Dosimetric benefit to organs at risk following margin reductions in nasopharyngeal carcinoma treated with intensity-modulated radiation therapy [J]. Chin J Cancer 34(5):189–197

Mertens R, Granzen B, Lassay L, Bucsky P, Hundgen M, Stetter G et al (2005) Treatment of nasopharyngeal carcinoma in children and adolescents: definitive results of a multicenter study (NPC-91-GPOH) [J]. Cancer 104(5):1083–1089

Ozcyar E, Selek U, Laskar S, Uzel O, Anacak Y, Ben-Arush M et al (2006) Treatment results of 165 pediatric patients with non-metastatic nasopharyngeal carcinoma: a Rare Cancer Network study [J]. Radiother Oncol 81(1):39–46

Penagaricano JA, Papanikolaou N (2003) Intensity-modulated radiotherapy for carcinoma of the head and neck [J]. Curr Oncol Rep 5(2):131–139

Peng G, Wang T, Yang KY, Zhang S, Zhang T, Li Q et al (2012) A prospective, randomized study comparing outcomes and toxicities of intensity-modulated radiotherapy vs. conventional two-dimensional radiotherapy for the treatment of nasopharyngeal carcinoma [J]. Radiother Oncol 104(3):286–293

Su SF, Han F, Zhao C, Chen CY, Xiao WW, Li JX et al (2012) Long-term outcomes of early-stage nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy alone [J]. Int J Radiat Oncol Biol Phys 82(1):327–333

Sullivan BO’, Rumble RB, Warde P (2012) Intensity-modulated radiotherapy in the treatment of head and neck cancer [J]. Clin Oncol 24(7):474–487

Tao CJ, Liu X, Tang LL, Mao YP, Chen L, Li WF et al (2013) Long-term outcome and late toxicities of simultaneous integrated boost-intensity modulated radiotherapy in pediatric and adolescent nasopharyngeal carcinoma [J]. Chin J Cancer 32(10):525–532

Toledano I, Graff P, Serre A, Boisselier P, Benson RJ, Orthalon C et al (2012) Intensity-modulated radiotherapy in head and neck cancer: results of the prospective study GÖRTEC 2004-03 [J]. Radiother Oncol 103(1):57–62

Tribus S, Bergelt C (2011) Intensity-modulated radiotherapy versus conventional and 3D conformal radiotherapy in patients with head and neck cancer: is there a worthwhile quality of life gain? [J]. Cancer Treat Rev 37(7):511–519

Wei WI, Sham JS (2005) Nasopharyngeal carcinoma [J]. Lancet 365(9476):2041–2054

Wei KR, Zheng RS, Zhang SW, Liang ZH, Ou ZX, Chen WQ (2014) Nasopharyngeal carcinoma incidence and mortality in China in 2010 [J]. Chin J Cancer 33(8):381–387
Wolden SL, Steinherz PG, Kraus DH, Zelefsky MJ, Pfister DG, Wollner N (2000) Improved long-term survival with combined modality therapy for pediatric nasopharynx cancer [J]. Int J Radiat Oncol Biol Phys 46(4):859–864
Young LS, Dawson CW (2014) Epstein-Barr virus and nasopharyngeal carcinoma [J]. Ch J Cancer 33(12):581–590
Zhang MX, Li J, Shen GP, Zou X, Xu JJ, Jiang R et al (2015) Intensity-modulated radiotherapy prolongs the survival of patients with nasopharyngeal carcinoma compared with conventional two-dimensional radiotherapy: A 10-year experience with a large cohort and long follow-up [J]. Eur J Cancer 51(17):2587–2595
Zhao C, Han F, Lu LX, Huang SM, Lin CG, Deng XW, et al. (2004) Intensity modulated radiotherapy for local-regional advanced nasopharyngeal carcinoma [J]. Ch J Cancer 23(11 Suppl):1532–7.
Zhou GQ, Yu XL, Chen M, Guo R, Lei Y, Sun Y et al (2013) Radiation-induced temporal lobe injury for nasopharyngeal carcinoma: a comparison of intensity-modulated radiotherapy and conventional two-dimensional radiotherapy [J]. PloS one 8(7):e67488